Abhasnee SobhonslidsukArtit UngkanontMahidol University2018-08-242018-08-242007-02-21World Journal of Gastroenterology. Vol.13, No.7 (2007), 1138-1140100793272-s2.0-34047102950https://repository.li.mahidol.ac.th/handle/123456789/24985It has been accepted that bone marrow transplantation (BMT) is the only curative therapeutic option for certain hematologic malignancies. The southeast Asia region is an endemic area of hepatitis B virus (HBV) infection; thus, BMT using a hepatitis B surface antigen (HBsAg)-positive donor is occasionally unavoidable. Organ transplantation using a HBsAg-positive donor can lead to post-transplantation de novo HBV infection and severe HBV-related hepatitis if no effective prophylactic measures are taken prior to and after transplantation. In this report, a four-level approach was designed for a patient with chronic myeloid leukemia, beginning with a booster HBV vaccination before performing BMT with a HBsAg-positive donor. Prior to BMT, the HBV viral load of the donor was reduced to an undetectable level by antiviral therapy. After BMT, hepatitis B immunoglobulin was administered intramuscularly for 1 wk together with a long-term antiviral drug, lamivudine. One year after discontinuation of lamivudine, the patient is still free of HBV infection. © 2007 The WJG Press. All rights reserved.Mahidol UniversityMedicineArticleSCOPUS10.3748/wjg.v13.i7.1138